Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00377585 · ClinicalTrials.gov registry record · Phase 2
Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 3,350
- Enrollment target
NCT00377585: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT00377585 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 3,350 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (2419% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00377585, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3,350 participants
- Enrollment target
Study Summary
The study is designed to demonstrate a meaningful difference in immunogenicity between the candidate adjuvanted vaccine compared to the licensed Fluarix vaccine in subjects aged 50 years and above. A control group in younger adults aged 18 to 40 years was included.
Interventions
- BIOLOGICAL Fluarix
- BIOLOGICAL adjuvanted influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,350 participants |
| Start Date | 2006-09-22 |
| Est. Completion | 2007-01-30 |
| Phase | Phase 2 |
What the finished NCT00377585 record still lists
NCT00377585 is an interventional study that assigns participants to a tested intervention. Its 3,350 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (2419% higher).
The record links to 0 conditions, and to 2 interventions - of which Fluarix is the first listed.
NCT00377585 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00377585 about?
NCT00377585 is a clinical study titled "Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population". The study is designed to demonstrate a meaningful difference in immunogenicity between the candidate adjuvanted vaccine compared to the licensed Fluarix vaccine in subjects aged 50 years and above. A control group in younger adults aged 18 to 40 years was included.
What is the current status of trial NCT00377585?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3,350 participants. The study started on 2006-09-22. Estimated completion is 2007-01-30.
What interventions are being tested in trial NCT00377585?
The interventions under investigation include: Fluarix (BIOLOGICAL), adjuvanted influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00377585?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00377585's enrollment target sits among peer trials
3,350 6th of 2000 higher than 1,995 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06880055 · 3,375 participants
Shield Post-Approval Study Protocol
- NCT03674307 · 3,306 participants · NA
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
- NCT03474029 · 3,400 participants · Phase 2
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
- NCT07142954 · 3,400 participants · Phase 3
Epidemiology and Biomarker Study in Alzheimer's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI